Replies to post #757163 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

dstock07734,

In my view, acquiring the Roswell commercial license may be just as significant as the UCLA DCVax-L license…

The two most relevant aspects of NWBO’s prospective value are:

⭐️ Combos with other agents that are already commercialized worldwide. (For one example, consider how the global commercial success of PD-1 blockade technology may impact dendritic cell platforms!) 🤔

⭐️ Multiple Patent-Fortified DC Platforms

Moffitt has interesting connections to Roswell and the two are collaborating on at least one active clinical trial today. At a minimum, Moffitt’s work has provided solid proof of concept for the value/need for DC technology in oncology, and I think we may soon learn more about the relationship between Moffitt and Roswell in the context of NWBO.

It is great to see the collaborative/cooperative efforts that have advanced DC technology from the Steinman era into a new era of combo therapies. NCI-designated cancer centers and multiple government agencies have worked together in developing dendritic cell-based platform technologies, which are now beginning to demonstrate efficacy in combo with established therapies that are already successful in the expanding global immunotherapy market.

Just a week after giving birth, Dallas Carroll was diagnosed with stage 4 breast cancer. Now, an experimental dendritic cell vaccine is giving her a shot at a cure—proof that innovative treatments are saving lives.

Read her full story: https://t.co/Hwq0iigidQ#MoffittImpact pic.twitter.com/tKUQWyVUcm

— Moffitt Cancer Center (@MoffittNews) March 5, 2025

Intratumoral delivery of dendritic cells combined with anti-HER2 antibodies is safe and effective in altering the tumor microenvironment and inducing dramatic tumor regression prior to chemotherapy in early-stage HER2-positive breast cancer. https://t.co/QgI6ZQfgtq pic.twitter.com/kLMjIDjwXj

— JAMA Oncology (@JAMAOnc) December 5, 2024